RWA Wealth Partners LLC Takes $2.51 Million Position in Avalo Therapeutics, Inc. $AVTX

Key Points

• RWA Wealth Partners LLC acquired 312,779 shares of Avalo Therapeutics, valued at about $2.5 million, representing approximately 2.89% ownership in the company.
• Analysts have positive outlooks for Avalo Therapeutics, with a consensus rating of "Buy" and an average target price of $30.00 following recent upgrades from HC Wainwright and Cantor Fitzgerald.
• Avalo Therapeutics reported a loss of $1.92 earnings per share in their latest earnings announcement, missing analysts' expectations by $0.49.

RWA Wealth Partners LLC bought a new position in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 312,779 shares of the company's stock, valued at approximately $2,505,000. RWA Wealth Partners LLC owned 2.89% of Avalo Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Velan Capital Investment Management LP acquired a new stake in shares of Avalo Therapeutics in the fourth quarter valued at approximately $817,000. BVF Inc. IL grew its position in shares of Avalo Therapeutics by 7.2% in the fourth quarter. BVF Inc. IL now owns 1,036,679 shares of the company's stock valued at $7,703,000 after purchasing an additional 69,679 shares during the last quarter. Allostery Investments LP acquired a new stake in shares of Avalo Therapeutics in the fourth quarter valued at approximately $545,000. Northern Trust Corp acquired a new stake in shares of Avalo Therapeutics in the fourth quarter valued at approximately $168,000. Finally, Tower Research Capital LLC TRC grew its position in shares of Avalo Therapeutics by 998.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company's stock valued at $31,000 after purchasing an additional 3,754 shares during the last quarter. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Stock Performance

NASDAQ:AVTX traded up $0.51 during trading hours on Friday, reaching $9.88. 148,455 shares of the company were exchanged, compared to its average volume of 338,847. Avalo Therapeutics, Inc. has a 52-week low of $3.39 and a 52-week high of $16.00. The stock has a 50 day simple moving average of $6.52 and a 200 day simple moving average of $6.08.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($1.92) earnings per share for the quarter, missing analysts' consensus estimates of ($1.43) by ($0.49). Analysts expect that Avalo Therapeutics, Inc. will post -19.07 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on AVTX shares. HC Wainwright upgraded shares of Avalo Therapeutics from a "hold" rating to a "buy" rating and set a $15.00 price target on the stock in a research report on Monday, June 2nd. Cantor Fitzgerald initiated coverage on shares of Avalo Therapeutics in a research note on Friday, August 15th. They set an "overweight" rating on the stock. Seven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Avalo Therapeutics has an average rating of "Buy" and a consensus price target of $30.00.

Avalo Therapeutics Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.